Loading...
•
Sep 30, 2020
Eagle Q3 2020 Earnings Report
Reported strong Q3 results driven by business model efficiency and key partnerships.
Key Takeaways
Eagle Pharmaceuticals reported a strong third quarter with total revenue of $49.9 million, driven by BELRAPZO and RYANODEX product sales growth and royalty revenue. Net income was $7.1 million, or $0.52 per basic share. The company is advancing multiple near-term product opportunities and welcomes new pharmaceutical executives to the team.
Total revenue for Q3 2020 was $49.9 million, compared to $41.1 million for Q3 2019.
Q3 2020 net income was $0.52 per basic and $0.51 per diluted share.
Adjusted non-GAAP net income for the third quarter of 2020 was $1.19 per basic and $1.17 per diluted share.
Japanese licensing partner, SymBio, received approval of TREAKISYM triggering $5.0 million milestone payment.
Eagle
Eagle
Forward Guidance
The guidance represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this press release.